Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Conclusion: Saroglitazar is safe and effective in prediabetes with dyslipidemia by exerting its dual lipid lowering and glycemic actions.
PMID: 30341861 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 2 | Endocrinology | General Medicine | Heart | India Health | Study